Exelixis: Tightly focused vision for genomics

As is generally the case with new discovery platforms, genomics has sprouted a plethora of companies, each of which is tackling the problem of translating genetic information into useful drug candidates from a slightly different angle.

The emphasis of these companies ranges from high throughput sequencing, to the use of large patient populations to hunt for disease markers in polygenic diseases, to the use of differential display to look at gene expression in diseased and healthy tissue...